| 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis JA Singh, G Guyatt, A Ogdie, DD Gladman, C Deal, A Deodhar, ... Journal of Psoriasis and Psoriatic Arthritis 4 (1), 31-58, 2019 | 722 | 2019 |
| Tofacitinib or adalimumab versus placebo for psoriatic arthritis P Mease, S Hall, O FitzGerald, D van der Heijde, JF Merola, ... New England Journal of Medicine 377 (16), 1537-1550, 2017 | 528 | 2017 |
| Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition JU Scher, A Ogdie, JF Merola, C Ritchlin Nature Reviews Rheumatology 15 (3), 153-166, 2019 | 287 | 2019 |
| Raynaud's phenomenon: pathogenesis and management R Bakst, JF Merola, AG Franks Jr, M Sanchez Journal of the American Academy of Dermatology 59 (4), 633-653, 2008 | 246 | 2008 |
| 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis … R Aggarwal, LG Rider, N Ruperto, N Bayat, B Erman, BM Feldman, ... Arthritis & Rheumatology 69 (5), 898-910, 2017 | 224 | 2017 |
| Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus R Furie, VP Werth, JF Merola, L Stevenson, TL Reynolds, H Naik, ... The Journal of clinical investigation 129 (3), 1359-1371, 2019 | 222 | 2019 |
| From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis AW Armstrong, MP Siegel, J Bagel, EE Boh, M Buell, KD Cooper, ... Journal of the American Academy of Dermatology 76 (2), 290-298, 2017 | 210 | 2017 |
| Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active … K Reich, KA Papp, A Blauvelt, RG Langley, A Armstrong, RB Warren, ... The Lancet 397 (10273), 487-498, 2021 | 209 | 2021 |
| Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded … KA Papp, JF Merola, AB Gottlieb, CEM Griffiths, N Cross, L Peterson, ... Journal of the American Academy of Dermatology 79 (2), 277-286. e10, 2018 | 203 | 2018 |
| Trial of upadacitinib and adalimumab for psoriatic arthritis IB McInnes, JK Anderson, M Magrey, JF Merola, Y Liu, M Kishimoto, ... New England Journal of Medicine 384 (13), 1227-1239, 2021 | 200 | 2021 |
| The psychosocial burden of psoriatic arthritis ME Husni, JF Merola, S Davin Seminars in arthritis and rheumatism 47 (3), 351-360, 2017 | 172 | 2017 |
| Dietary recommendations for adults with psoriasis or psoriatic arthritis from the medical board of the national psoriasis foundation: a systematic review AR Ford, M Siegel, J Bagel, KM Cordoro, A Garg, A Gottlieb, LJ Green, ... JAMA dermatology 154 (8), 934-950, 2018 | 169 | 2018 |
| Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment DJB Kurtzman, NA Wright, J Lin, AN Femia, JF Merola, M Patel, ... JAMA dermatology 152 (8), 944-945, 2016 | 137 | 2016 |
| Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails JF Merola, A Qureshi, ME Husni Dermatologic therapy 31 (3), e12589, 2018 | 136 | 2018 |
| Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial CT Ritchlin, A Kavanaugh, JF Merola, G Schett, JU Scher, RB Warren, ... The Lancet 395 (10222), 427-440, 2020 | 135 | 2020 |
| Distinguishing rheumatoid arthritis from psoriatic arthritis JF Merola, LR Espinoza, R Fleischmann RMD open 4 (2), e000656, 2018 | 131 | 2018 |
| A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process L Thorlacius, JR Ingram, B Villumsen, S Esmann, JS Kirby, AB Gottlieb, ... British Journal of Dermatology 179 (3), 642-650, 2018 | 128 | 2018 |
| Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation CL Mallucci, MD Jenkinson, EJ Conroy, JC Hartley, M Brown, J Dalton, ... The Lancet 394 (10208), 1530-1539, 2019 | 121 | 2019 |
| Comorbidities associated with psoriatic arthritis: review and update LM Perez-Chada, JF Merola Clinical Immunology 214, 108397, 2020 | 118 | 2020 |
| Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis B Lockshin, Y Balagula, JF Merola Journal of the American Academy of Dermatology 79 (2), 345-352, 2018 | 114 | 2018 |
